Vet Med - Czech, 2023, 68(2):83-89 | DOI: 10.17221/49/2022-VETMED

Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a PomeranianCase Report

L Choi1, JY Choi2, HY Yoon2, K Bae3, KA Yoon3, JH Kim1
1 Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea
2 Department of Veterinary Surgery, College of Veterinary Medicine, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea
3 Department of Veterinary Biochemistry, College of Veterinary Medicine, Konkuk University, Gwangjin-gu, Seoul, Republic of Korea

A 10-year-old spayed female Pomeranian dog was referred for hepatic mass evaluation. Blood tests revealed mildly elevated alkaline phosphatase activities. Computed tomography revealed a mass with multiple nodules on the right hepatic medial lobe adjacent to the caudal vena cava; histopathology confirmed mixed hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). Because of incomplete resection, adjuvant therapy was recommended. As tumour cells showed PDGFR-α, c-Kit, and FGFR1 overexpression, the anticancer effect of tyrosine kinase inhibitors was evaluated on the cells; toceranib was the most effective and was administered starting with an extra-labelled dose. The dog remained stable for 2.3 years with mild adverse effects. To our knowledge, this is the first successful clinical application of toceranib in a dog with mixed HCC-CC.

Keywords: anticancer effect; biliary carcinoma; canine

Received: May 17, 2022; Accepted: January 16, 2023; Prepublished online: February 23, 2023; Published: February 24, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Choi L, Choi J, Yoon H, Bae K, Yoon K, Kim J. Adjuvant therapy with toceranib for hepatocellular carcinoma and cholangiocarcinoma in a Pomeranian. Vet Med - Czech. 2023;68(2):83-89. doi: 10.17221/49/2022-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    Supplementary files:

    Download file2022-049_ESM.pdf

    File size: 970.22 kB

    References

    1. Barber NA, Afzal W, Akhtari M. Hematologic toxicities of small molecule tyrosine kinase inhibitors. Target Oncol. 2011 Dec;6(4):203-15. Go to original source... Go to PubMed...
    2. Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):204-8. Go to original source... Go to PubMed...
    3. Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Vet Res. 2013 Sep 30;9:190. Go to original source... Go to PubMed...
    4. Cavalcanti JVJ, Hasbach A, Barnes K, Dange RB, Patterson J, Saavedra PV. Skin depigmentation associated with toceranib phosphate in a dog. Vet Dermatol. 2017 Aug;28(4):400-e95. Go to original source... Go to PubMed...
    5. Cullen JM, Popp JA. Tumors of the liver and gall bladder. In: Meuten DJ, editor. Tumors in domestic animals. Ames, USA: Iowa State Press; 2002. p. 483-508. Go to original source...
    6. Dominguez PA, Dervisis NG, Cadile CD, Sarbu L, Kitchell BE. Combined gemcitabine and carboplatin therapy for carcinomas in dogs. J Vet Intern Med. 2009 Jan-Feb;23(1):130-7. Go to original source... Go to PubMed...
    7. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002 Sep 1;100(5):1532-42. Go to original source... Go to PubMed...
    8. Hammer AS, Sikkema DA. Hepatic neoplasia in the dog and cat. Vet Clin North Am Small Anim Pract. 1995 Mar;25(2):419-35. Go to original source... Go to PubMed...
    9. Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): Beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr;8(2):256-65. Go to original source... Go to PubMed...
    10. Lang L. FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology. 2008 Feb;134(2):379. Go to original source... Go to PubMed...
    11. LeBlanc AK, Atherton M, Bentley RT, Boudreau CE, Burton JH, Curran KM, Dow S, Giuffrida MA, Kellihan HB, Mason NJ, Oblak M, Selmic LE, Selting KA, Singh A, Tjostheim S, Vail DM, Weishaar KM, Berger EP, Rossmeisl JH, Mazcko C. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021 Jun;19(2):311-52. Go to original source... Go to PubMed...
    12. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008 Oct;48(4):1312-27. Go to original source... Go to PubMed...
    13. Matsuyama A, Takagi S, Hosoya K, Kagawa Y, Nakamura K, Deguchi T, Takiguchi M. Impact of surgical margins on survival of 37 dogs with massive hepatocellular carcinoma. N Z Vet J. 2017 Sep;65(5):227-31. Go to original source... Go to PubMed...
    14. Maximin S, Ganeshan DM, Shanbhogue AK, Dighe MK, Yeh MM, Kolokythas O, Bhargava P, Lalwani N. Current update on combined hepatocellular-cholangiocarcinoma. Eur J Radiol Open. 2014 Sep 6;1:40-8. Go to original source... Go to PubMed...
    15. Moeini A, Cornella H, Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer. 2012 Sep;1(2):83-93. Go to original source... Go to PubMed...
    16. Patnaik AK, Hurvitz AI, Lieberman PH. Canine hepatic neoplasms: A clinicopathologic study. Vet Pathol. 1980 Sep;17(5):553-64. Go to original source... Go to PubMed...
    17. Seebacher NA, Stacy AE, Porter GM, Merlot AM. Clinical development of targeted and immune based anti-cancer therapies. J Exp Clin Cancer Res. 2019 Apr 11;38(1):156. Go to original source... Go to PubMed...
    18. Stavraka C, Rush H, Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): An update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma. 2018 Dec 28;6:11-21. Go to original source... Go to PubMed...
    19. Terai K, Ishigaki K, Kagawa Y, Okada K, Yoshida O, Sakurai N, Heishima T, Asano K. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009-2021). J Am Vet Med Assoc. 2022 Apr 27;260(13):1668-74. Go to original source... Go to PubMed...
    20. Vail DM, Thamm D, Liptak J. Withrow and MacEwan's small animal clinical oncology. 6th ed. London, UK: Elsevier; 2019.
    21. Wu CH, Yong CC, Liew EH, Tsang LL, Lazo M, Hsu HW, Ou HY, Yu CY, Chen TY, Huang TL, Concejero AM, Chen CL, Cheng YF. Combined hepatocellular carcinoma and cholangiocarcinoma: Diagnosis and prognosis after resection or transplantation. Transplant Proc. 2016 May;48(4):1100-4. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content